НАСЛЕДИЕ ФУНДАМЕНТАЛЬНОЙ НАУКИ В ФЕДЕРАЛЬНОМ ГОСУДАРСТВЕННОМ БЮДЖЕТНОМ УЧРЕЖДЕНИИ «НАЦИОНАЛЬНЫЙ МЕДИЦИНСКИЙ ИССЛЕДОВАТЕЛЬСКИЙ ЦЕНТР ОНКОЛОГИИ» МИНЗДРАВА РОССИИ, "Наука Юга России"

Шихлярова, А. И.; Франциянц, Е.М.; Kaplieva, Irina V.; Zhukova, Galina V.

doi:10.7868/s25000640220413

Cited by 2 publications

(4 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…За уровень статистической значимости принимали p<0,05. Сбор клинической информации, биологического материала, соблюдение правовых норм и правил выполнены, согласно разработанным алгоритмам действий подразделений исследовательских и клинических групп ФГБУ «НМИЦ онкологии» Минздрава России [28]. Note: * -statistically significant differences in LAG-3 with different ICT regimens (p<0.05); ** -statistically significant differences in LAG-3 in comparison with the IIA group (p<0.001); *** -statistically significant differences in LAG-3 in comparison with the IIA-RB group (p<0.001); **** -statistically significant differences in LAG-3 in comparison with the IIA-FCR group (p<0.001).…”

Section: материал и методыunclassified

“…Южно-Российский онкологический журнал. 2020; 1(3): [27][28][29][30][31][32][33][34][35]Selyutina O.N.,Novikova I.A.,Maksimov A.Yu.,Nozdricheva A.S.,Abakumova S.V. Morphological and immunofenotypic features of the monoclonal population of B-lymphocytes in chronic lymphocytic leukemia.…”

Section: заключениеmentioning

confidence: 99%

“…South Russian Journal of Cancer. 2020; 1(3): [27][28][29][30][31][32][33][34][35]]. doi: 10.37748/2687-0533-2020-1-3-3.…”

Section: заключениеmentioning

confidence: 99%

See 2 more Smart Citations

Expression of LAG-3 on B-lymphocytes as a marker for prediction of response to therapy in patients with chronic lymphocytic leukemia

et al. 2023

View full text Add to dashboard Cite

Purpose: to study the level of LAG-3 expression on B-lymphocytes and the feasibility of using it as a marker for predicting response to therapy in patients with chronic lymphocytic leukemia (CLL).Material and Methods. The study included 40 patients with newly diagnosed CLL. All patients were divided into two groups: group I: patients with Binet stage A, who did not receive therapy and group II: patients with Binet stage C, who received immunochemotherapy in RB and FCR regimes. According to the treatment regimen and hematological response to therapy, 4 subgroups were distinguished: IIA-RB, IIA-FCR, IIB-RB, and IIB-FCR. The control group consisted of 20 people matched in age and gender without cancer. The immunophenotype, level of B-lymphocytes, LAG-3 expression, and the minimal residual disease in group II after the 6th course of immunochemotherapy were initially determined in all groups by flow cytometry. The data were evaluated using Statistica 13.0.Results. Compared to the control group, the LAG-3 expression on B-lymphocytes was found in all groups of CLL patients before treatment. The expression level was higher in patients with Binet stage C than in patients with Binet stage. The data demonstrated differences in the level of LAG-3 expression in patients with different hematological responses to therapy. The initially higher level of LAG-3 expression on B-lymphocytes was observed in patients with Binet stage C CLL with an unfavorable response to therapy. A good hematological response was found can be achieved at the level of LAG-3 expression within 14.57 ± 0.66 % regardless of the therapy regimen, and unfavorable response to therapy at the level of 41.95 ± 1.62 %.Conclusion. The initial level of LAG-3 expression on B-lymphocytes in patients with CLL can be used as a marker for predicting and monitoring response to treatment, regardless of the immunochemotherapy regimen used.

show abstract

Section: материал и методыunclassified

Section: заключениеmentioning

confidence: 99%

See 1 more Smart Citation

Expression of LAG-3 on B-lymphocytes as a marker for prediction of response to therapy in patients with chronic lymphocytic leukemia

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Сюда относятся интенсивные схемы лучевой и химиотерапии. Однако применение данных видов лечения увеличивает риск осложнений, к которым относят и химиотоксические кардиопатии, включающие в себя дисфункцию миокарда, сердечную недостаточность, гипертонию, вазоспастическую и тромбоэмболическую ишемию, аритмии разного вида и внезапную сердечную смерть [3,4]. В этой связи актуально своевременное выявление и лечение осложнений со стороны сердечно-сосудистой системы (ССС) у больных, получающих курсы химиотерапии в комплексе с хирургическими методами лечения.…”

unclassified

Changes in the level of cardiomarkers in the development of acute myocardial infarction on the background of chemotherapy of a patient with tongue cancer

Guskova,

Vladimirova,

Sycheva

et al. 2021

jour

View full text Add to dashboard Cite

Cancer is one of the leading causes of death and disability worldwide. Timely diagnosis and the introduction of new effective treatments, including intensive radiation and chemotherapy regimens, have significantly improved survival forecasts in recent years. At the same time, the use of these types of treatment increases the risk of complications, one of which includes chemotoxic cardiopathies. In this regard, timely detection and treatment of complications from the cardiovascular system in patients receiving chemotherapy courses in combination with surgical methods of treatment is important. This paper presents an assessment of the significance of the use of cardiomarkers in the early diagnosis of acute myocardial infarction that developed during chemotherapy in a patient with tongue cancer with a complicated cardiac history. Patient M., 45 years old, was admitted for surgical treatment for cancer of the tongue St. IVA, T4aN1M0, cl. gr. 2. Planned laboratory and instrumental studies were performed. Contraindications for surgical treatment were not identified. A preoperative course of chemotherapy was performed, against the background of which the patient's condition worsened with symptoms of acute cardiopathy. A second ECG was urgently performed, as a result of which an increase in the ST segment in III, aVF was established, as well as a study of the concentration of cardiomarkers: highly sensitive troponin I, N-terminal propeptide of natriuretic hormone, creatine phosphokinase MB, myoglobin, the dynamics of changes in the level of which indicated the development of acute coronary syndrome. The complex application of diagnostic procedures, including the determination of the level of cardiomarkers, made it possible to timely diagnose the development of acute type 1 myocardial infarction in a patient with tongue cancer on the background of chemotherapy. When analyzing the entire array of clinical and laboratory data, the leading initiating factor that played a decisive role in the development of myocardial infarction in this case was, in our opinion, a preoperative course of polychemotherapy with paclitaxel and carboplatin, which have cardiotoxicity. Thus, the category of patients with an initial unfavorable background, due to a common malignant process and the presence of a history of cardiodisfunction, requires more careful preparation for preoperative courses of polychemotherapy, including cardiotropic therapy with mandatory monitoring of the level of the main cardiomarkers. The most significant changes were in the levels of creatine phosphokinase MB, troponin I, and myoglobin, which were recorded in the first hours of myocardial infarction. An association was found between an increase in troponin I concentration and an increase in the ST segment of the electrocardiogram.

show abstract

Cited by 2 publications

References 16 publications

Expression of LAG-3 on B-lymphocytes as a marker for prediction of response to therapy in patients with chronic lymphocytic leukemia

Expression of LAG-3 on B-lymphocytes as a marker for prediction of response to therapy in patients with chronic lymphocytic leukemia

Changes in the level of cardiomarkers in the development of acute myocardial infarction on the background of chemotherapy of a patient with tongue cancer

Contact Info

Product

Resources

About